Abstract
Question What is the median time to clearance of SARS-CoV-2 among cancer patients according to currently used criteria?
Findings In this single-institution retrospective cohort study, the median time to SARS-CoV-2 clearance was 50 days using the ASCO/CDC criteria of 2 negative RT-PCR assays >24 hours apart. Using alternative criteria of 1 negative RT-PCR assay (UK-NICE) or CDC clinical criteria (10 days after first positive RT-PCR and 3 days after last symptoms), median clearance times were 31 days and 13 days, respectively.
Meaning SARS-CoV-2 clearance times differ substantially depending on criteria used and may be prolonged in cancer patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: The work was partially funded by National Institutes of Health/National Cancer Institute grants K08 CA248473 (MLBP) and R37 CA218707 (DBC). Disclosure of Potential Conflicts of Interest: JMP: Received honoraria from Radius, research grant support from Breast Cancer Research Foundation, institutional research support from Genentech, Sanofi, Odonate Therapeutics, all outside submitted work. DBC: Reports personal fees (consulting fees and honoraria) and nonfinancial support (institutional research support) from Takeda/Millennium Pharmaceuticals, and AstraZeneca, and Pfizer, as well as nonfinancial support (institutional research support) from Merck Sharp and Dohme Corporation, Merrimack Pharmaceuticals, Bristol-Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals and Tesaro, all outside the submitted work. MLBP: Received honoraria from Bayer, Exelixis and Agios, travel support from Halozyme, AstraZeneca and Exelixis, research support from Bayer, institutional research support from Taiho, AstraZeneca, BeiGene, Berg, Merck, all outside the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data collection was performed as part of an institutional COVID-19 registry project and approved by the institutional review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Blinded data available for review on request
